Jardiance Off-Label Uses with Evidence Levels

How Empagliflozin Works: The Mechanism Behind Off-Label Interest

Empagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) protein in the proximal renal tubule, which normally reabsorbs roughly 90% of filtered glucose. By inhibiting this transporter, the drug forces urinary glucose excretion of approximately 60 to 80 grams per day at therapeutic doses 1. That caloric loss (240 to 320 kcal/day) contributes to modest weight reduction, but the drug's clinical reach extends well beyond glycosuria.

SGLT2 inhibition triggers a cascade of secondary effects: osmotic diuresis lowers intravascular volume, reducing preload on the heart. Tubuloglomerular feedback restores afferent arteriolar tone, lowering intraglomerular pressure. Ketone body production rises slightly, providing an alternative myocardial fuel substrate. Uric acid clearance increases through competition at the URAT1 transporter. These pleiotropic actions explain why empagliflozin has attracted investigation across conditions that have nothing to do with blood sugar.

The 2015 EMPA-REG OUTCOME trial (N=7,020) demonstrated a 38% relative risk reduction in cardiovascular death among patients with type 2 diabetes and established cardiovascular disease 1. That result was the first signal that SGLT2 inhibitors offered organ protection independent of glucose lowering. It opened the door to every off-label application discussed below.

NAFLD and MASLD: Level B Evidence

Empagliflozin reduces hepatic fat content by 20% to 30% in patients with type 2 diabetes and concurrent non-alcoholic fatty liver disease, based on multiple randomized trials using MRI-derived proton density fat fraction (MRI-PDFF) as the primary endpoint 2. The E-LIFT trial (N=50) showed a significant reduction in liver fat over 20 weeks compared to standard care, with a mean absolute decrease of 4.1% in MRI-PDFF 2.

The mechanism likely involves reduced hepatic de novo lipogenesis, improved insulin sensitivity, and caloric deficit from glycosuria. A 2021 meta-analysis of SGLT2 inhibitors in NAFLD covering 12 studies (combined N=850) found consistent reductions in ALT, AST, and hepatic steatosis scores 3. The American Association for the Study of Liver Diseases (AASLD) does not yet include SGLT2 inhibitors in formal MASLD treatment guidelines, but the 2023 AACE/AGA clinical guidance recognizes their potential benefit in patients with co-existing type 2 diabetes and MASLD.

No Phase III trial has been powered specifically for histologic endpoints (fibrosis regression or NASH resolution) with empagliflozin. Until such data emerge, this remains a Level B indication: supported by small RCTs and mechanistic plausibility, but lacking definitive outcomes evidence.

Hyperuricemia and Gout Prevention: Level B Evidence

SGLT2 inhibitors lower serum uric acid by 1.0 to 1.5 mg/dL on average. The mechanism is competitive inhibition at URAT1 and GLUT9 urate transporters in the proximal tubule, increasing renal uric acid clearance 4. In EMPA-REG OUTCOME, empagliflozin reduced serum uric acid by approximately 0.8 mg/dL compared to placebo, and a post-hoc analysis linked this reduction to part of the observed cardiovascular benefit 1.

A population-based cohort study using U.S. claims data (N=295,907 new SGLT2 inhibitor users) found a 36% lower risk of incident gout flares compared to DPP-4 inhibitor users (HR 0.64 to 95% CI 0.57 to 0.72) 5. Dr. Chio Yokose from Massachusetts General Hospital, a lead investigator in gout epidemiology, has noted: "SGLT2 inhibitors may represent a dual-benefit strategy in patients who have both cardiometabolic disease and hyperuricemia."

For patients with recurrent gout who also carry an indication for empagliflozin (diabetes, heart failure, or CKD), the drug serves a practical dual purpose. Prescribing it solely for gout prophylaxis in an otherwise healthy patient remains unsupported by prospective trial data. Evidence level: B.

Autosomal Dominant Polycystic Kidney Disease (ADPKD): Level C Evidence

The rationale for SGLT2 inhibition in ADPKD rests on preclinical work showing that polycystin-deficient renal epithelial cells rely heavily on aerobic glycolysis. Reducing glucose availability via SGLT2 blockade may slow cyst growth. A 2023 Phase II crossover trial (EMPA-PKD, N=41) tested empagliflozin 25 mg daily in ADPKD patients with eGFR above 30 mL/min 6. Over 18 months, empagliflozin was well tolerated and produced a non-significant trend toward slower total kidney volume (TKV) growth.

The larger IMPEDE-PKD trial (NCT05374291) is currently randomizing approximately 850 ADPKD patients to empagliflozin, a ketogenic metabolic intervention, or placebo. Results are expected after 2027. Until then, empagliflozin for ADPKD sits at Level C: mechanistically plausible, early-phase human data available, no efficacy signal confirmed. The Endocrine Society's 2024 clinical practice advisory does not recommend routine SGLT2 inhibitor use in ADPKD outside of clinical trials.

Obesity Without Diabetes: Level B Evidence

Empagliflozin produces modest weight loss of 2 to 3 kg over 24 to 52 weeks in most trials, driven primarily by caloric loss through glycosuria and mild osmotic diuresis 7. In patients without diabetes, urinary glucose excretion is lower (because filtered glucose loads are smaller), and weight loss tends to plateau at 1.5 to 2.0 kg. That magnitude is clinically insignificant as a standalone obesity treatment.

Where empagliflozin shows more promise is as an adjunct. A 2024 retrospective analysis of GLP-1 receptor agonist plus SGLT2 inhibitor combination therapy found an additional 1.8 kg weight loss over GLP-1 RA alone at 12 months, along with improved blood pressure and reduced lower-extremity edema 8. For patients on semaglutide or tirzepatide who develop peripheral edema or whose blood pressure remains above target, adding empagliflozin addresses both concerns while contributing incremental weight reduction.

The 2024 American Association of Clinical Endocrinology (AACE) obesity algorithm lists SGLT2 inhibitors as a "consider in combination" option for patients with BMI above 27 kg/m² and co-existing cardiovascular risk factors 9. This recommendation is notably limited. Nobody prescribes Jardiance alone expecting 10% body weight loss. Evidence level: B, strictly for adjunctive use in metabolically complex patients.

Heart Failure with Preserved Ejection Fraction (HFpEF) and Diastolic Dysfunction: Level A Evidence (Now FDA-Approved)

Empagliflozin earned FDA approval for heart failure with preserved ejection fraction based on the EMPEROR-Preserved trial (N=5,988), which showed a 21% reduction in the composite of cardiovascular death or heart failure hospitalization (HR 0.79 to 95% CI 0.69 to 0.90, P<0.001) 10. This is now an on-label indication, but the specific subphenotype of isolated diastolic dysfunction (Grade I or II) without overt HF diagnosis remains off-label.

Some cardiologists prescribe empagliflozin to patients with echocardiographic evidence of impaired relaxation (E/e' ratio above 14, elevated LA volume index) who do not yet meet formal HFpEF diagnostic criteria. Dr. Milton Packer from Baylor University Medical Center has written: "The distinction between diastolic dysfunction and HFpEF is often a matter of staging, not biology. SGLT2 inhibitors likely benefit the entire continuum." 10

For pre-clinical diastolic dysfunction, evidence remains extrapolated from the EMPEROR-Preserved population. No trial has specifically enrolled patients with isolated diastolic dysfunction but no HF diagnosis. Evidence level for this specific off-label subset: B.

Post-Acute Kidney Injury Renoprotection: Level C Evidence

Acute kidney injury (AKI) survivors face a 2- to 3-fold higher risk of progressing to CKD stage 4 or 5 within five years. SGLT2 inhibitors' renoprotective effects (reduced intraglomerular pressure, lower tubular workload, decreased albuminuria) make them a logical candidate for post-AKI secondary prevention 11.

A 2023 retrospective cohort study from Taiwan (N=12,406 AKI survivors) found that SGLT2 inhibitor initiation within 90 days of AKI was associated with a 30% lower risk of major adverse kidney events at 2 years compared to matched controls (HR 0.70 to 95% CI 0.58 to 0.85) 11. These observational data are encouraging, but confounding by indication is a serious concern: patients deemed "well enough" to start an SGLT2 inhibitor after AKI may inherently carry better prognoses.

The EMPA-KIDNEY trial (N=6,609) included a post-AKI subgroup analysis showing consistent benefit, though the subgroup was small 12. Prospective trials specifically designed for post-AKI initiation are still in planning. Evidence level: C.

Diabetic Cardiomyopathy Without Heart Failure Diagnosis: Level C Evidence

Patients with longstanding type 2 diabetes develop structural myocardial changes (increased LV mass, myocardial fibrosis, impaired strain) even before ejection fraction drops or symptoms appear. This entity, termed diabetic cardiomyopathy, lacks an FDA-approved treatment. Sub-analyses of EMPA-REG OUTCOME demonstrated that empagliflozin reduced left ventricular mass index by 2.6 g/m² over 52 weeks compared to placebo, measured by cardiac MRI in a subset of 97 patients 13.

These structural improvements occurred rapidly (within 3 months) and persisted, suggesting a direct myocardial effect rather than a secondary consequence of blood pressure reduction. The leading hypothesis involves improved myocardial energetics through increased ketone body utilization and reduced sodium-hydrogen exchanger (NHE1) activity. However, no trial has demonstrated that early empagliflozin use in subclinical diabetic cardiomyopathy prevents progression to symptomatic heart failure. Evidence level: C.

Evidence Summary Table

| Off-Label Use | Evidence Level | Key Data Source | Typical Dose | |---|---|---|---| | NAFLD/MASLD | B | E-LIFT trial, multiple small RCTs | 10 to 25 mg daily | | Hyperuricemia/gout | B | EMPA-REG post-hoc, large cohort | 10 to 25 mg daily | | ADPKD | C | EMPA-PKD Phase II | 25 mg daily | | Obesity adjunct | B | Retrospective combo data | 10 to 25 mg daily | | Isolated diastolic dysfunction | B | Extrapolated from EMPEROR-Preserved | 10 mg daily | | Post-AKI renoprotection | C | Taiwan cohort, EMPA-KIDNEY subgroup | 10 mg daily | | Diabetic cardiomyopathy | C | EMPA-REG OUTCOME MRI substudy | 10 to 25 mg daily |

Safety Considerations for Off-Label Prescribing

Empagliflozin's safety profile is well characterized across more than 30,000 patient-years in RCTs. The most clinically relevant risks for off-label populations include genital mycotic infections (5% to 10% incidence, higher in women), euglycemic diabetic ketoacidosis (rare but reported at approximately 0.1% in non-diabetic HF trials), volume depletion in elderly patients or those on loop diuretics, and Fournier gangrene (extremely rare, FDA boxed warning class-level) 14.

For non-diabetic patients, the ketoacidosis risk requires specific counseling: patients should hold empagliflozin during acute illness, surgery, or prolonged fasting. The American Diabetes Association recommends a "sick day rule" pause of 3 days before and after any procedure requiring general anesthesia 15.

eGFR thresholds matter. Empagliflozin's glycosuric effect diminishes below eGFR 45 mL/min/1.73 m², but cardiorenal protective effects persist to eGFR 20 mL/min based on EMPA-KIDNEY data 12. Clinicians prescribing off-label for renoprotection should not discontinue the drug solely because eGFR drops below 45, provided the patient tolerates it.

Baseline labs before starting off-label empagliflozin should include a comprehensive metabolic panel, urinalysis, and HbA1c (to rule out undiagnosed diabetes or pre-diabetes, which might make the prescription on-label instead). Patients with recurrent UTIs, active foot ulcers, or type 1 diabetes should not receive empagliflozin off-label given the unfavorable risk-benefit ratio in those populations.